Viscosupplementation involves injecting hyaluronic acid products into the knee joint of patients suffering from osteoarthritis in order to supplement endogenous synovial fluid viscosity and alleviate pain. These injections aim to restore normal lubrication within the joint, contain anti-inflammatory properties and may stimulate cartilage repair. The rising prevalence of osteoarthritis and knee osteoarthritis along with the preference for minimally invasive procedures have propelled the demand for viscosupplementation treatment in Canada.

Key Takeaways

Key players: Sanofi, Anika Therapeutics, Bioventus, Ferring B.V and Zimmer Biomet are major players in the Canada Viscosupplementation Market. Sanofi's Synvisc One and Synvisc provides single-injection and three-injection treatment respectively.

Key opportunities: Rising geriatric population prone to osteoarthritis, marketing initiatives by industry players and favorable reimbursement policies present lucrative opportunities for market growth.

Get more insights- Canada Viscosupplementation Market

Author Bio:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.

(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)